(Q50688251)
Statements
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results (English)
Francesca Botta
Erika Di Betta
Gianluca Aliberti
Sergio Bavusi
Alessandro Massimo Gianni
Emilio Bombardieri